IL135469A0 - Methods for treating psychosis associated with glucocorticoid related dysfunction - Google Patents

Methods for treating psychosis associated with glucocorticoid related dysfunction

Info

Publication number
IL135469A0
IL135469A0 IL13546998A IL13546998A IL135469A0 IL 135469 A0 IL135469 A0 IL 135469A0 IL 13546998 A IL13546998 A IL 13546998A IL 13546998 A IL13546998 A IL 13546998A IL 135469 A0 IL135469 A0 IL 135469A0
Authority
IL
Israel
Prior art keywords
methods
psychosis associated
treating psychosis
related dysfunction
glucocorticoid
Prior art date
Application number
IL13546998A
Other languages
English (en)
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of IL135469A0 publication Critical patent/IL135469A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13546998A 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction IL135469A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6097397P 1997-10-06 1997-10-06
PCT/US1998/020906 WO1999017779A1 (fr) 1997-10-06 1998-10-05 Methodes de traitement de la psychose associee a un dysfonctionnement lie aux glucocorticoides

Publications (1)

Publication Number Publication Date
IL135469A0 true IL135469A0 (en) 2001-05-20

Family

ID=22032889

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13546998A IL135469A0 (en) 1997-10-06 1998-10-05 Methods for treating psychosis associated with glucocorticoid related dysfunction
IL135469A IL135469A (en) 1997-10-06 2000-04-04 Use of glucocorticoid receptor antagonists in the preparation of drugs for the treatment of psychosis associated with glucocorticoid-related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL135469A IL135469A (en) 1997-10-06 2000-04-04 Use of glucocorticoid receptor antagonists in the preparation of drugs for the treatment of psychosis associated with glucocorticoid-related disorders

Country Status (17)

Country Link
US (2) US6150349A (fr)
EP (1) EP1023074B1 (fr)
JP (3) JP2001518509A (fr)
KR (2) KR100840957B1 (fr)
CN (3) CN1528315A (fr)
AT (1) ATE332696T1 (fr)
AU (1) AU747956B2 (fr)
CA (1) CA2302586C (fr)
CY (1) CY1106330T1 (fr)
DE (1) DE69835225T2 (fr)
DK (1) DK1023074T3 (fr)
ES (1) ES2268792T3 (fr)
IL (2) IL135469A0 (fr)
NO (1) NO327233B1 (fr)
NZ (1) NZ503250A (fr)
PT (1) PT1023074E (fr)
WO (1) WO1999017779A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (fr) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19oxidoprogestérone (21-OH-60P) en tant qu'antiglucocorticoide
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
US6620802B1 (en) * 1999-11-23 2003-09-16 Corcept Therapeutics, Inc. Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
EP1325022B1 (fr) * 2000-09-18 2006-11-02 Applied Research Systems ARS Holding N.V. Procede de preparation de 21-hydroxy-6,19-oxydoprogesterone (21oh-6op)
JP2004525135A (ja) 2001-03-23 2004-08-19 コーセプト セラピューティクス， インコーポレイテッド 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
US7163934B2 (en) 2001-05-04 2007-01-16 Corcept Therapeutics, Inc. Methods for treating delirium glucocorticoid receptor-specific antagonists
JP2005512949A (ja) * 2001-05-04 2005-05-12 コーセプト セラピューティクス， インコーポレイテッド グルココルチコイドレセプターに特異的なアンタゴニストを使用して、せん妄を処置する方法
CN1853722A (zh) * 2001-07-23 2006-11-01 科塞普特治疗公司 预防由抗精神病药物引起的体重增加的方法
MXPA04001893A (es) * 2001-08-31 2005-03-07 Corcept Therapeutics Inc Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down.
IL161248A0 (en) * 2001-10-26 2004-09-27 Akzo Nobel Nv USE OF (11beta,17beta)-11-(1,3-BENZODIOXOL-5-YL) 17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
JP2005513024A (ja) * 2001-11-23 2005-05-12 アクゾ・ノベル・エヌ・ベー グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療
US7326697B2 (en) * 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
WO2004004653A2 (fr) * 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methodes de traitement de la psychose associee a une therapie aux interferon $g(a)
AU2003299311A1 (en) * 2002-12-18 2004-07-09 University Of Zurich Treatment of neuro-psychiatric disorders
AU2004208842B2 (en) * 2003-02-04 2009-05-28 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
WO2006060736A2 (fr) * 2004-12-03 2006-06-08 The Children's Hospital Of Philadelphia Composition destinee a accroitre l'effet therapeutique d'un medicament antiepileptique et utilisation de cette composition
CN100588393C (zh) * 2004-12-15 2010-02-10 上海三合生物技术有限公司 赛米司酮类用于治疗抑郁症的用途
US20060229505A1 (en) * 2005-04-08 2006-10-12 Mundt James C Method and system for facilitating respondent identification with experiential scaling anchors to improve self-evaluation of clinical treatment efficacy
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP1987814A1 (fr) * 2007-04-30 2008-11-05 Exelgyn Compositions pharmaceutiques de mifepristone et leurs procédé de préparation
RU2327448C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Средство для лечения зависимости от этилового спирта и/или от наркотиков, фармацевтическая композиция, активный ингредиент фармацевтической композиции, способ лечения зависимости от этилового спирта и/или от наркотиков для лечения психосоматических и неврологических осложнений у алкоголиков и/или наркоманов
JP5663303B2 (ja) * 2007-06-15 2015-02-04 リサーチ トライアングル インスティテュート Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
US11103514B2 (en) * 2010-05-26 2021-08-31 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
WO2012106514A2 (fr) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc Système et méthode de diagnostic et de traitement
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
CN107530435A (zh) * 2015-03-02 2018-01-02 科赛普特治疗学股份有限公司 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CA2984623C (fr) 2015-05-18 2023-05-02 Corcept Therapeutics, Inc. Procedes permettant de diagnostiquer et d'evaluer un traitement du syndrome de cushing
CN109843183B (zh) * 2016-10-21 2022-04-12 西铁城时计株式会社 检测装置
MX2022006633A (es) 2019-12-11 2022-06-24 Corcept Therapeutics Inc Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant.
US11878025B2 (en) * 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5348729A (en) * 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
JP2000511404A (ja) * 1996-04-09 2000-09-05 ビー・テイー・ジー・インターナシヨナル・リミテツド 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs

Also Published As

Publication number Publication date
KR100840957B1 (ko) 2008-06-24
JP2009051858A (ja) 2009-03-12
KR100804558B1 (ko) 2008-02-20
DK1023074T3 (da) 2006-11-06
KR20010024431A (ko) 2001-03-26
CN1272788A (zh) 2000-11-08
IL135469A (en) 2007-03-08
JP2009132743A (ja) 2009-06-18
WO1999017779A1 (fr) 1999-04-15
AU9683298A (en) 1999-04-27
CA2302586A1 (fr) 1999-04-15
DE69835225D1 (de) 2006-08-24
US6150349A (en) 2000-11-21
NZ503250A (en) 2001-09-28
JP2001518509A (ja) 2001-10-16
AU747956B2 (en) 2002-05-30
CN1187053C (zh) 2005-02-02
CY1106330T1 (el) 2011-10-12
KR20070032822A (ko) 2007-03-22
EP1023074A1 (fr) 2000-08-02
CA2302586C (fr) 2008-06-10
DE69835225T2 (de) 2007-07-05
ATE332696T1 (de) 2006-08-15
EP1023074B1 (fr) 2006-07-12
JP5180125B2 (ja) 2013-04-10
NO327233B1 (no) 2009-05-18
NO20001744D0 (no) 2000-04-05
CN1528315A (zh) 2004-09-15
CN1919199A (zh) 2007-02-28
ES2268792T3 (es) 2007-03-16
PT1023074E (pt) 2006-12-29
US6362173B1 (en) 2002-03-26
NO20001744L (no) 2000-04-05

Similar Documents

Publication Publication Date Title
IL135469A0 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
IL139672A (en) Glucocorticoid receptor antagonists for the tretment of dementia
PL360932A1 (en) Chemokine receptor binding heterocyclic compounds
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
HUP0201184A3 (en) Use of selective antagonists of the alpha1b-adrenergic receptor for improvement of sexual dysfunction
HK1035739A1 (en) Soluble t cell receptor
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
EP1109542A4 (fr) Antagonistes nitroses et nitrosyles des recepteurs alpha-adrenergiques, compositions et methodes d'utilisation
WO2002076390A3 (fr) Methodes de traitement des troubles du stress au moyen d'antagonistes specifiques du recepteur des glucocorticoides
DK1408981T3 (da) Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler
AP2003002924A0 (en) 2,5-diarylpyrazines, 2,5 - diarylpyridines and 2,5 - diarylpyrimidines as CRF1 receptor modulators
IL144031A0 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
NZ504471A (en) An Ox receptor distinct from known alpha 2-adenoreceptors and imidazoline receptors (I1 and I2) with an affinity for compounds of the oxazoline class
HK1062533A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
IL158744A0 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
DE69803883T2 (de) Neue verbindungen, welche antagonisten sind für p2-purinorezeptor 7-transmembran (tm) g-protein gekoppelte rezeptoren
EP1414445A4 (fr) Agoniste partiel sur le site modulateur de glycine du recepteur mdna servant a traiter les dysfonctionnements cognitifs
AU2001250528A1 (en) Agonists/antagonists of the gpr56 receptor as appetite control agents
DE60135773D1 (en) Assays
AU2002219192A1 (en) Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
DK0814803T3 (da) Anvendelse af steroidale estrogenreceptorantagonister til fertilitetskontrol hos mænd
WO2005009382A3 (fr) Therapie par antiglucocorticoide destinee a prevenir une lesion neurologique chez les enfants prematures
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed